LOGIN  |  REGISTER
Recursion
Compass Therapeutics

Zomedica to Participate in the Lytham Partners Investor Select Conference

January 24, 2023 | Last Trade: US$0.14 0.0023 -1.63

ANN ARBOR, MI / ACCESSWIRE / January 24, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or "Company") announced today that the Company will be participating in the Lytham Partners Investor Select Conference taking place virtually on January 31, 2023.

Company Webcast

The Company's webcast presentation will be available for viewing at 9:00am ET on Tuesday, January 31, 2023, at https://wsw.com/webcast/lytham7/zom/1898244, and subsequently on the Company's website at www.ZOMEDICA.com.

1x1 Meetings

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at This email address is being protected from spambots. You need JavaScript enabled to view it. or register at https://www.lythampartners.com/winter2023invreg/.

About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) is a veterinary health company creating products for companion animals by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio will include innovative diagnostics and medical devices that emphasize patient health and practice health. It is Zomedica's mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.

Follow Zomedica

Contacts

Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447)
Or 407-491-4498
This email address is being protected from spambots. You need JavaScript enabled to view it.

C4 Therapeutics

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page